



BioNova Submits Investigational New Drug Application for BN301 for the Treatment of Hematologic Malignancies in China

SHANGHAI, China, July. 1, 2022 - BioNova Pharmaceuticals Limited (BioNova), a company dedicated to the discovery, development and commercialization of innovative medicines for the treatment of diseases with unmet medical needs, today announced that it has submitted an investigational new drug (IND) application for BN301 (STRO-001) for the treatment of hematologic malignancies to the China National Medical Products Administration (NMPA).

BN301 is a well-defined, novel, homogeneous antibody-drug conjugate (ADC) comprised of a human aglycosylated anti-CD74 IgG1 antibody and 2 noncleavable maytansinoid drug-linkers. Through a licensing agreement with Sutro Biopharma, Inc. (Sutro, NASDAQ: STRO) in October 2021, BioNova gained the option to obtain exclusive rights to develop and commercialize BN301 in Greater China territory, including mainland China, Hong Kong, Macau and Taiwan. STRO-001 is currently progressing through a Phase 1 study (BCM-1) in the US.

“This IND application marked another major milestone for BioNova not because it further strengthens our pipeline in hematologic malignancies, but broadens BioNova’s expertise into biologic drugs of cutting-edge technology.” Said Ye Hua, M.D., Founder and CEO of BioNova, “Based on its novel mechanism and early-phase clinical data in the US, BN301 has the potential to become an effective and safe treatment for patients who had advanced B-cell non-Hodgkin’s lymphoma, multiple myeloma or acute myeloid leukemia. Our clinical team has already engaged world class medical centers and key-opinion leaders in the disease area for the preparation of clinical trial initiation in China.”

About BioNova

BioNova Pharmaceuticals Limited is a privately held clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative medicines for cancer and other life-threatening diseases with high unmet medical needs. Headquartered in Shanghai, BioNova is a fast-growing company of which robust pipeline is built upon internal R&D programs, collaborations with and acquisitions from partners of cutting-edge technology. With a highly capable and experienced team in combination with substantial funding, BioNova is committed to delivering high-quality innovative medicines to patients in China and globally.

For further information, please refer to <https://www.bionovapharma.com>

Contact BioNova

Claire Shan

IR & PR Manager

Email: claire.shan@bionovapharma.com

Tel: +86 (21) 5090 1280